A new version of Abbott Laboratories' ( ABT) HIV drug Kaletra has been approved by the Food and Drug Administration. The tablet form of the drug allows patients to take fewer pills per day, doesn't require refrigeration and can be taken with or without food, unlike the previous version of the drug. Kaletra was first approved by the FDA in September 2000. According to Abbott, Kaletra is the top-prescribed drug among protease inhibitors, a class of drugs that keep the HIV virus from multiplying within the body. Abbott's shares were up 17 cents to $42.92 Monday.